Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

that tumor-cell associated HA may be a better predictor of PEGPH20 combination treatment effect compared to stromal associated HA.

Treatment was generally well tolerated, and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. The most common adverse events for PEGPH20 were muscle spasms, myalgia and arthralgia (all grade 1/2). There was no evidence of new toxicities when used in combination with gemcitabine and the pharmacokinetics of PEGPH20 with gemcitabine was consistent with the pharmacokinetics of PEGPH20 as a single agent. Additionally, the pharmacodynamic and pharmacokinetics results support the dosing regimen of PEGPH20 at 3µg/kg, which is being used in an on-going Phase 2 trial.

Halozyme has initiated a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 in combination with nab-paclitaxel and gemcitabine to confirm the combination treatment effect (ORR, PFS and OS) based on HA levels. The study plans to enroll approximately 124 patients with stage IV pancreatic ductal adenocarcinoma. Halozyme is also developing an HA diagnostic tool to be used in this study to evaluate the potential treatment benefit based on tumor HA levels at baseline. This diagnostic approach may enable additional PEGPH20 combination clinical studies in other HA-rich tumor types.

About PEGPH20

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render the tumor more vulnerable to therapy as well as inhibit tumor growth.

About Pancreatic Cancer

In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the low
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
(Date:3/26/2015)... 2015 Huntington Memorial Hospital is the first ... aortic valve replacement (TAVR), a minimally invasive replacement of ... way to replace an aortic valve without a chest ... The procedure is performed by a dedicated ... Alex) Durairaj , MD, interventional cardiologist and Robbin ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... (OTC Bulletin Board: SNDZ ), announced today that ... with key brokers and funds.  The purpose of these meetings ... to facilitate funding for Sunridge to execute its business plan ... for this project," states G. Richard Smith, CEO of Sunridge. ...
... NEW YORK, Aug. 24 Regenicin, ... a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, ... has agreed to join the company,s board of directors. ... efforts of PermaDerm™, Regenicin,s proprietary autologous cultured ...
Cached Medicine Technology:Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors 2
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... March 27, 2015 Bleeding is ... undergoing percutaneous coronary intervention (PCI), resulting in increased ... a “risk-treatment paradox,” in which the highest-risk PCI ... are treated less often with bleeding avoidance strategies ... Luke’s Mid America Heart Institute asked the question ...
(Date:3/27/2015)... 27, 2015 Healthpointe is proud to ... M.D., is now treating knee and hip joint disorders ... , Long Beach, and La Mirada. Dr. Stanley Katz ... and hip joint disorders as well as chronic conditions ... in returning his patients back to their normal lives. ...
(Date:3/27/2015)... York, NY (PRWEB) March 27, 2015 Ticket Down ... in Concert in 2015. After a phenomenal and highly ... show "Nashville" will be going out on tour again in 2015 ... The tour gets underway on April 29th in New York City ... AZ at the Comerica Theatre on May 10th. , Fans of ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... sleep leads to excessive daytime sleepiness, altered mood, and ... accidents. A recent study suggests that obese and overweight ... . ,For the study researchers examined patients' total ... body mass index. More than 1,000 patients completed a ...
... the reason some adolescents experience depression could be abnormal ... between ages 13 to 18, half of who had ... was performed to measure the volume of each teen’s ... hippocampus of patients with depression was, on average, 17 ...
... studies have shown inhaled corticosteroids can reduce the mortality ... results from a study conducted by researchers from the ... than 2,650 patients with COPD who were prescribed inhaled ... period. Nearly 5,400 patients who had never used inhaled ...
... series of laboratory experiments, researchers say they have now ... oil fights cancer.// ,Oleic acid dramatically cut ... of Her-2/neu are associated with aggressive tumors in many ... boosts the effectiveness of the antibody treatment trastuzumab (Herceptin), ...
... world is infected with tuberculosis every second and someone dies ... have discovered easier tests to detect this deadly disease in ... generally done with a gastric lavage. It's an invasive test ... a sputum sample. Sputum is what comes up when you ...
... study shows men who consume three or more alcoholic drinks ... ischemic stroke develops // when an artery in the brain ... than 38,000 participants for 14 years. The male participants responded ... identified 412 cases of ischemic stroke among the study participants. ...
Cached Medicine News:
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... Used for stenting the urethra after ... provide postoperative drainage of the bladder. ... is of sufficient length to allow ... diaper, keeping the inside diaper dry ...
Medicine Products: